UA107678C2 - Процес очищення рекомбінантного людського еритропоетину (епо), епо, очищений таким чином, та фармацевтична композиція, що містить його - Google Patents
Процес очищення рекомбінантного людського еритропоетину (епо), епо, очищений таким чином, та фармацевтична композиція, що містить йогоInfo
- Publication number
- UA107678C2 UA107678C2 UAA201205042A UAA201205042A UA107678C2 UA 107678 C2 UA107678 C2 UA 107678C2 UA A201205042 A UAA201205042 A UA A201205042A UA A201205042 A UAA201205042 A UA A201205042A UA 107678 C2 UA107678 C2 UA 107678C2
- Authority
- UA
- Ukraine
- Prior art keywords
- epo
- recombinant human
- rectification
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Винахід належить до способу очищення біологічно активних ізоформ глікозилованого еритропоетину (ЕПО) від суміші складних білків, що містить етап аніонообмінної хроматографії, а також етап катіонообмінної хроматографії, які розділені етапом хроматографії з оберненою фазою, причому етап катіонообмінної хроматографії іде за етапом хроматографії з оберненою фазою. Також винахід належить до препарату біологічно активних ізоформ заявленого глікозилованого ЕПО та фармацевтичної композиції, що містить заявлений препарат ЕПО.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09012120 | 2009-09-23 | ||
PCT/EP2010/005839 WO2011035914A1 (en) | 2009-09-23 | 2010-09-23 | Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same |
Publications (1)
Publication Number | Publication Date |
---|---|
UA107678C2 true UA107678C2 (uk) | 2015-02-10 |
Family
ID=41566362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201205042A UA107678C2 (uk) | 2009-09-23 | 2010-09-23 | Процес очищення рекомбінантного людського еритропоетину (епо), епо, очищений таким чином, та фармацевтична композиція, що містить його |
Country Status (14)
Country | Link |
---|---|
US (1) | US20120264688A1 (uk) |
EP (1) | EP2480569B1 (uk) |
JP (1) | JP5728016B2 (uk) |
KR (1) | KR20120117728A (uk) |
CN (1) | CN102712688B (uk) |
AU (1) | AU2010297530B2 (uk) |
BR (1) | BR112012006602A2 (uk) |
CA (1) | CA2775012A1 (uk) |
EA (1) | EA022396B1 (uk) |
IL (1) | IL218721A0 (uk) |
MX (1) | MX2012003558A (uk) |
UA (1) | UA107678C2 (uk) |
WO (1) | WO2011035914A1 (uk) |
ZA (1) | ZA201202491B (uk) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101443257B1 (ko) * | 2011-10-18 | 2014-09-19 | 주식회사 종근당 | 낮은 등전점을 갖는 에리스로포이에틴 유사체의 정제방법 |
US10066001B2 (en) * | 2013-03-15 | 2018-09-04 | Apotex Inc. | Enhanced liquid formulation stability of erythropoietin alpha through purification processing |
WO2014204023A1 (ko) * | 2013-06-17 | 2014-12-24 | 씨제이헬스케어 주식회사 | 신규한 다베포에틴 알파의 정제 방법 |
US11066678B2 (en) | 2013-07-18 | 2021-07-20 | Children's Hospital Medical Center | Methods of improving titer in transfection-based production systems using eukaryotic cells |
US10078081B2 (en) | 2014-03-05 | 2018-09-18 | GlycoScientific LLC | Isotopically labeled glycans and methods for producing the same |
JP6906497B2 (ja) * | 2016-03-09 | 2021-07-21 | Jcrファーマ株式会社 | 変異型ヒトエリスロポエチンの製造方法 |
WO2017169978A1 (ja) * | 2016-03-31 | 2017-10-05 | 株式会社カネカ | 精製されたネコ由来エリスロポエチンの製造方法 |
WO2019005645A1 (en) | 2017-06-26 | 2019-01-03 | Michael Foods, Inc. | YELLOW EGG FRACTIONATION |
EP3613486B1 (de) * | 2018-08-24 | 2020-10-07 | UGA Biopharma GmbH | Verfahren und anlage zur reinigung von epo und/oder einem epo-derivat |
CN115015415A (zh) * | 2022-05-30 | 2022-09-06 | 科兴生物制药股份有限公司 | 重组人***的含量检测方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin |
US4677195A (en) * | 1985-01-11 | 1987-06-30 | Genetics Institute, Inc. | Method for the purification of erythropoietin and erythropoietin compositions |
US4667016A (en) | 1985-06-20 | 1987-05-19 | Kirin-Amgen, Inc. | Erythropoietin purification |
IL79176A (en) | 1985-06-20 | 1992-06-21 | Kirin Amgen Inc | Process for the recovery of erythropoietin from a fluid |
EP0248656B1 (en) | 1986-06-04 | 1993-03-31 | Director-General of the Agency of Industrial Science and Technology | Composition for cell cultivation and use thereof |
JP2520681B2 (ja) | 1986-08-04 | 1996-07-31 | ザ ユニバーシティ オブ ニュー サウス ウェールズ | 生合成のヒトの成長ホルモン製品 |
US4954437A (en) | 1986-09-15 | 1990-09-04 | Integrated Genetics, Inc. | Cell encoding recombinant human erythropoietin |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
EP0343635B1 (en) | 1988-05-25 | 1994-08-24 | Teijin Limited | Process for continuously culturing adherent animal cells |
US5856298A (en) * | 1989-10-13 | 1999-01-05 | Amgen Inc. | Erythropoietin isoforms |
KR100221066B1 (ko) | 1989-10-13 | 1999-10-01 | 스튜어트 엘.왓트 | 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물 |
DK0779362T4 (da) | 1989-12-22 | 2012-07-30 | Serono Lab | DNA-konstruktioner til aktivering og modifikation af endogene geners ekspression |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
DE4115722A1 (de) | 1991-05-14 | 1992-11-19 | Boehringer Mannheim Gmbh | Serumfreies medium zur kultivierung von saeugerzellen |
PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
IL118201A (en) | 1995-05-11 | 2004-12-15 | Roche Diagnostics Gmbh | Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof |
JP4220125B2 (ja) * | 1997-12-03 | 2009-02-04 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 高い比活性を有するエリスロポエチン |
BR9917606A (pt) * | 1998-11-06 | 2002-12-31 | Bio Sidus S A | Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento |
CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
PT1311285E (pt) * | 2000-05-15 | 2005-06-30 | Hoffmann La Roche | Composicao farmaceutica liquida contendo um derivado de eritropoietina |
US20020045192A1 (en) * | 2001-09-19 | 2002-04-18 | St. Jude Children's Research Hospital | Arf and HDM2 interaction domains and methods of use thereof |
US6930086B2 (en) * | 2001-09-25 | 2005-08-16 | Hoffmann-La Roche Inc. | Diglycosylated erythropoietin |
ES2525945T3 (es) * | 2001-11-28 | 2015-01-02 | Sandoz Ag | Purificación cromatográfica de eritropoyetina humana recombinante |
WO2003080852A1 (en) | 2002-03-26 | 2003-10-02 | Lek Pharmaceutical And Chemical Company D.D. | Process for the preparation of a desired erythropoietin glyco-isoform profile |
EP1428878B1 (en) | 2002-12-13 | 2008-08-20 | Bioceuticals Arzneimittel AG | Process for the production and purification of erythropoietin |
EP1537876A1 (en) | 2003-12-01 | 2005-06-08 | BioGeneriX AG | Erythropoietin solution formulation |
BRPI0417916A (pt) * | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | proteìna de fusão de fc-eritropoietina com farmacocinética melhorada |
US20090311247A1 (en) * | 2005-01-25 | 2009-12-17 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
KR20090090328A (ko) * | 2006-11-09 | 2009-08-25 | 시나게바 바이오파르마, 코포레이션 | 조류 유래 에리트로포이어틴 |
US20090105462A1 (en) * | 2006-11-09 | 2009-04-23 | Ivarie Robert D | Glycosylated erythropoietin |
CA2737026C (en) * | 2008-09-26 | 2019-12-24 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
-
2010
- 2010-09-23 MX MX2012003558A patent/MX2012003558A/es not_active Application Discontinuation
- 2010-09-23 EA EA201290135A patent/EA022396B1/ru not_active IP Right Cessation
- 2010-09-23 AU AU2010297530A patent/AU2010297530B2/en not_active Ceased
- 2010-09-23 CN CN201080051883.9A patent/CN102712688B/zh not_active Expired - Fee Related
- 2010-09-23 BR BR112012006602A patent/BR112012006602A2/pt not_active IP Right Cessation
- 2010-09-23 EP EP10759588.6A patent/EP2480569B1/en active Active
- 2010-09-23 WO PCT/EP2010/005839 patent/WO2011035914A1/en active Application Filing
- 2010-09-23 JP JP2012530170A patent/JP5728016B2/ja not_active Expired - Fee Related
- 2010-09-23 UA UAA201205042A patent/UA107678C2/uk unknown
- 2010-09-23 CA CA2775012A patent/CA2775012A1/en not_active Abandoned
- 2010-09-23 KR KR1020127009211A patent/KR20120117728A/ko not_active Application Discontinuation
- 2010-09-23 US US13/497,500 patent/US20120264688A1/en not_active Abandoned
-
2012
- 2012-03-19 IL IL218721A patent/IL218721A0/en unknown
- 2012-04-04 ZA ZA2012/02491A patent/ZA201202491B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2012003558A (es) | 2012-07-03 |
EA201290135A1 (ru) | 2012-10-30 |
BR112012006602A2 (pt) | 2019-09-24 |
AU2010297530A1 (en) | 2012-04-26 |
CN102712688B (zh) | 2015-06-24 |
IL218721A0 (en) | 2012-06-28 |
US20120264688A1 (en) | 2012-10-18 |
KR20120117728A (ko) | 2012-10-24 |
JP2013505276A (ja) | 2013-02-14 |
ZA201202491B (en) | 2012-12-27 |
AU2010297530B2 (en) | 2013-12-19 |
WO2011035914A1 (en) | 2011-03-31 |
JP5728016B2 (ja) | 2015-06-03 |
CN102712688A (zh) | 2012-10-03 |
EA022396B1 (ru) | 2015-12-30 |
EP2480569B1 (en) | 2016-04-13 |
EP2480569A1 (en) | 2012-08-01 |
CA2775012A1 (en) | 2011-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA107678C2 (uk) | Процес очищення рекомбінантного людського еритропоетину (епо), епо, очищений таким чином, та фармацевтична композиція, що містить його | |
EP2415749A4 (en) | NEW SALVIANOLIC ACID CONNECTION L, PREPARATION METHOD AND USE | |
MX343756B (es) | Microorganismo que produce o-fosfoserina y metodo para producir l-cisteina o derivados de la misma a partir de o-fosfoserina usando los mismos. | |
SG10201805198TA (en) | 18f - fluciclovine compositions in citrate buffers | |
MX359475B (es) | Composiciones antitranspirantes y desodorantes. | |
MY173663A (en) | Compositions and methods for biological production of fatty acid derivatives | |
BR112015003594A2 (pt) | material compósito à base de óxido de zircônio | |
WO2013072932A3 (en) | Oral care compositions | |
BR112012033404A2 (pt) | polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos. | |
MX2011009369A (es) | 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
BR112013032786A2 (pt) | restauração dentária, método para a sua produção e lingote | |
NZ733366A (en) | Purification of iduronate-2-sulfatase | |
TN2011000370A1 (en) | Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof | |
UA109949C2 (uk) | Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання | |
NZ707829A (en) | Thermally reactive thermoplastic intermediate product and method of manufacturing thereof | |
WO2012057529A3 (en) | Method for purifying human granulocyte-colony stimulating factor from recombinant e. coli | |
UA104031C2 (uk) | Диференціація мезенхімальних стовбурових клітин | |
WO2012053794A3 (en) | Microorganism producing o-phosphoserine and method of producing l-cysteine or derivatives thereof from o-phosphoserine using the same | |
MX2011008825A (es) | 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3. | |
NZ607149A (en) | Galacto-oligosaccharide-containing composition and a method of producing it | |
MX337432B (es) | Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero. | |
NZ601142A (en) | Composition for improving brain function and method for improving brain function | |
MX2021008396A (es) | Composiciones de administración farmacéutica y sus usos. | |
MX2011008662A (es) | 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3. | |
ATE443722T1 (de) | Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung |